e-therapeutics and Novo Nordisk extend collaboration

1 August 2019

Danish diabetes giant Novo Nordisk (NOV: N) and UK-based e-therapeutics (AIM: ETX) have extended their research collaboration.

To date, the companies have been using e-therapeutics' proprietary network-driven drug discovery (NDD) platform to discover potentially new biological mechanisms and therapeutic approaches for a specific area of type 2 diabetes.

Under the amended agreement, e-therapeutics will now also use its new genome-associated interaction networks (GAINs) technology to analze population genomics data from patients with type 2 diabetes. This is the first research agreement to use the platform.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK